Navigation Links
Yale New Haven Health System Implements ActX Genomic Decision Support Within Epic
Date:8/29/2017

As part of a transformative effort to bring precision medicine to the bedside and the exam room, Yale New Haven Health System (YNHHS) of New Haven, Connecticut is adding ActX Genomic Decision Support to its Electronic Health Record, Epic.

The ActX platform includes evidence based clinical decision support content covering drug-genome interactions, hereditary genetic risks and carrier status. YNHHS will begin by integrating the ActX Genomic Decision Support for pharmacogenomics with the electronic health record used through its five hospitals and over 400 ambulatory sites, including the 1541 bed Academic Medical Center – Yale New Haven Hospital. This integration brings genomics to the bedside by leveraging the ActX service to enable real-time checking of each prescription against the patient’s genetic profile. Within their normal Epic order workflow, prescribers will receive alerts about potential adverse reactions, drug efficacy, or dosing based on the patient’s genetic findings. An embedded Genomic Profile for each patient will also be available within Epic.

The initial focus for real-time pharmacogenomics will be within behavioral health, cardiology, infectious disease, and pediatrics departments. By implementing the ActX genomic decision support service, YNHH will use the latest genetic knowledge to help its physicians choose the best medications for patients by avoiding adverse reactions and ineffective medications.

“Yale has been a pioneer in genomics and its applications for clinical use. Genomic health, where we can deliver actionable interpretations directly to clinical providers, is key to Yale New Haven Health’s vision for precision medicine. We plan to provide this valuable information directly to our physicians across the health system so we can continue to deliver the best care possible to our patients,” notes Allen Hsiao, Chief Medical Information Officer for Yale New Haven Health and Yale School of Medicine.

“We are proud to partner with Yale New Haven Health System to bring genomic decision support and precision medicine to such a prestigious academic hospital,” said Dr. Andrew Ury, CEO of ActX. “The ActX Platform for Epic will help make actionable genomics practical for Yale New Haven physicians and their patients."

YNHHS’s implementation of ActX within Epic marks a big step toward making personalized medicine the norm for its patients. To learn more about ActX, visit http://www.actx.com.

About ActX
ActX helps physicians make better decisions about medical treatment, using patients’ genetic information. Integrated into the physician’s software tools and workflow, ActX analyzes the patient’s genetic information in real time and alerts physicians about drug-genome interactions, actionable hereditary risks and carrier status. For more information, visit http://www.actx.com, email info(at)actx(dot)com or call (888) 998-2289.

About Yale New Haven Health
A leading integrated delivery system with five hospitals and a Physician management group comprising the largest health system in Connecticut. Yale New Haven Hospital (YNHH) is a non-profit, 1,541-bed tertiary academic medical center receiving national and international referrals. Yale New Haven Hospital includes Smilow Cancer Hospital, Yale New Haven Children's Hospital and Yale New Haven Psychiatric Hospital. Bridgeport Hospital has 383 licensed beds plus 42 beds licensed under Yale New Haven Children’s Hospital. Greenwich Hospital is a 206-bed regional hospital, serving Fairfield County, Connecticut and Westchester County, New York. All three hospitals are a major academic affiliate of Yale University School of Medicine. Laurence + Memorial Hospital is a 280 bed regional hospital located in the eastern part of CT, Westerly Hospital is a 60 bed hospital serving the western shoreline of RI, Northeast Medical Group (NEMG), is a physician group affiliated with YNHHS. NEMG includes community physicians in Fairfield and New Haven counties in Connecticut, as well as Westchester County, NY

Contact Information:
Joe Sichel
Marketing Specialist
ActX
joe.sichel(at)actx(dot)com
888-998-2289

Read the full story at http://www.prweb.com/releases/2017/08/prweb14639556.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Biohaven Files Registration Statement for Proposed Public Offering of its Common Shares
2. Biohaven Enrolls First Patient in Pivotal Trial of BHV-4157 in Patients With Hereditary Spinocerebellar Ataxia
3. Biohaven BHV-0223 is Granted Orphan Drug Designation in the Treatment of Amyotrophic Lateral Sclerosis
4. Biohaven Announces Orphan Drug Designation Request Granted for BHV-4157
5. Biohaven Appoints Jim Engelhart as Chief Financial Officer
6. Biohaven Appoints John Tilton as Chief Commercial Officer
7. Portages Biohaven orphan drug designation request granted for the treatment of spinocerebellar ataxia
8. Biohaven Announces Orphan Drug Designation Request Granted for the Treatment of Spinocerebellar Ataxia
9. Portages Biohaven Announces Expedited Development Path for BHV-0223 Following Successful Pre-IND Interaction with FDA
10. Biohaven Announces Expedited Development Path for BHV-0223 Following Successful Pre-IND Interaction With FDA
11. Portages Biohaven announces positive results from phase 1 study with BHV-0223
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... SANTA CRUZ, Calif. , Oct. 10, 2017 /PRNewswire/ ... SBIR grant from the NIH to develop RealSeq®-SC (Single ... preparation kit for profiling small RNAs (including microRNAs) from ... Cell Analysis Program highlights the need to accelerate development ... "New techniques for ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series will feature ... Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population estimates nearing ... how to continue to feed a growing nation. At the same time, many of ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... for microscopy and surface analysis, Nanoscience Instruments is now expanding into Analytical ... broad range of contract analysis services for advanced applications. Services will leverage ...
(Date:10/6/2017)... ... October 06, 2017 , ... On Tuesday, October 24th, ABC² ... the first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker will be ... and open to the public, but registration is required. , WHAT: ABC² ...
Breaking Biology Technology:
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...
Breaking Biology News(10 mins):